Co-Authors
This is a "connection" page, showing publications co-authored by Antonio Di Biagio and Andrea Gori.
Connection Strength
0.511
-
PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. PLoS One. 2017; 12(7):e0181433.
Score: 0.181
-
Determinants of patient and health care services delays for tuberculosis diagnosis in Italy: a cross-sectional observational study. BMC Infect Dis. 2018 Dec 20; 18(1):690.
Score: 0.050
-
Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2018 10; 41(4):247-255.
Score: 0.049
-
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. New Microbiol. 2018 Apr; 41(2):112-117.
Score: 0.048
-
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One. 2018; 13(2):e0192627.
Score: 0.047
-
Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. PLoS One. 2017; 12(12):e0189425.
Score: 0.047
-
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project. PLoS One. 2017; 12(6):e0179254.
Score: 0.045
-
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Combination Treatment in Patients with HIV/HCV Co-Infection: Results of an Italian Compassionate Use Program. Clin Infect Dis. 2017 03 01; 64(5):680-683.
Score: 0.044